Search research articles
Contact Us
Filters
Showing results (261-270 of 738) with videos related to
Page
of 74
Sort By:
Cancers
|
December 9, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response
John Nemunaitis, Laura Stanbery, David Willoughby, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 25, 2025
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
Michelle D S Lightfoot, Maria M Rubinstein, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 6, 2025
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment
Vivek Podder, Rachel N Grisham, Robert L Coleman, et al.
Gynecologic Oncology
|
September 18, 2010
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
Leslie M Randall, Bradley J Monk, James Moon, et al.
Data in Brief
|
April 30, 2020
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, George Wang, et al.
Arxiv
|
March 30, 2023
Robust single-shot 3D fluorescence imaging in scattering media with a simulator-trained neural network
Jeffrey Alido, Joseph Greene, Yujia Xue, et al.
Gynecologic Oncology Research and Practice
|
May 28, 2016
In vitro chemoresponse in metachronous pairs of gyneclologic cancers
Heather J Dalton, James Fiorica, Candace K McClure, et al.
Oncology and Therapy
|
November 5, 2024
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
Bradley J Monk, Sophie van Mens, Oliver Hale, et al.
Gynecologic Oncology
|
January 12, 2020
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, George Wang, et al.
Current Problems in Cancer
|
June 4, 2023
Selinexor in patients with advanced and recurrent endometrial cancer
Giorgio Bogani, Bradley J Monk, Robert L Coleman, et al.
Page
of 74
Search research articles
Search
Showing results (261-270 of 738) with videos related to
Sort By:
Page
of 74
Cancers
|
December 9, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response
John Nemunaitis, Laura Stanbery, David Willoughby, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 25, 2025
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
Michelle D S Lightfoot, Maria M Rubinstein, Bradley J Monk, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 6, 2025
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment
Vivek Podder, Rachel N Grisham, Robert L Coleman, et al.
Gynecologic Oncology
|
September 18, 2010
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
Leslie M Randall, Bradley J Monk, James Moon, et al.
Data in Brief
|
April 30, 2020
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, George Wang, et al.
Arxiv
|
March 30, 2023
Robust single-shot 3D fluorescence imaging in scattering media with a simulator-trained neural network
Jeffrey Alido, Joseph Greene, Yujia Xue, et al.
Gynecologic Oncology Research and Practice
|
May 28, 2016
In vitro chemoresponse in metachronous pairs of gyneclologic cancers
Heather J Dalton, James Fiorica, Candace K McClure, et al.
Oncology and Therapy
|
November 5, 2024
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
Bradley J Monk, Sophie van Mens, Oliver Hale, et al.
Gynecologic Oncology
|
January 12, 2020
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer
Bradley J Monk, Thomas J Herzog, George Wang, et al.
Current Problems in Cancer
|
June 4, 2023
Selinexor in patients with advanced and recurrent endometrial cancer
Giorgio Bogani, Bradley J Monk, Robert L Coleman, et al.
Page
of 74